Does SATRALIZUMAB-MWGE Cause Hepatic function abnormal? 14 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Hepatic function abnormal have been filed in association with SATRALIZUMAB-MWGE. This represents 1.3% of all adverse event reports for SATRALIZUMAB-MWGE.
14
Reports of Hepatic function abnormal with SATRALIZUMAB-MWGE
1.3%
of all SATRALIZUMAB-MWGE reports
0
Deaths
6
Hospitalizations
How Dangerous Is Hepatic function abnormal From SATRALIZUMAB-MWGE?
Of the 14 reports, 6 (42.9%) required hospitalization.
Is Hepatic function abnormal Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SATRALIZUMAB-MWGE. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does SATRALIZUMAB-MWGE Cause?
Neuromyelitis optica spectrum disorder (181)
Off label use (87)
Urinary tract infection (87)
Pneumonia (64)
Covid-19 (47)
No adverse event (47)
Fatigue (41)
Headache (36)
Pain (36)
Arthralgia (31)
What Other Drugs Cause Hepatic function abnormal?
NIVOLUMAB (1,131)
PEMBROLIZUMAB (1,079)
METHOTREXATE (1,054)
CABOZANTINIB S-MALATE (912)
CYCLOPHOSPHAMIDE (824)
BEVACIZUMAB (769)
PACLITAXEL (603)
LENVATINIB (528)
ATORVASTATIN (520)
CYCLOSPORINE (508)
Which SATRALIZUMAB-MWGE Alternatives Have Lower Hepatic function abnormal Risk?
SATRALIZUMAB-MWGE vs SAXAGLIPTIN
SATRALIZUMAB-MWGE vs SCHOLL'S INGROWN TOENAIL PAIN RELIEVER
SATRALIZUMAB-MWGE vs SCOPOLAMINE
SATRALIZUMAB-MWGE vs SCOPOLAMINE HYDROBROMIDE
SATRALIZUMAB-MWGE vs SEBELIPASE ALFA